© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
December 15, 2020
The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.
December 08, 2020
Phase 1 data suggest the anti–PD-1 immune checkpoint inhibitor is safe and tolerable in the neoadjuvant setting for patients with nonmetastatic high-risk clear cell renal cell carcinoma.
December 07, 2020
No new safety signals were reported with the androgen receptor pathway inhibitor.
Patients undergoing pouch diversion reported significantly more regret than patients undergoing neobladder or ileal conduit.
December 05, 2020
Over half of patients who achieved a complete response to Jelmyto maintained that response at 12 months.
The in-depth interview covers the data that led to the NMIBC approval, outlines the appropriate patient population for pembrolizumab, and reviews side-effect management with the immune checkpoint inhibitor.
Researchers examined the prevalence of germline mutations, as well as clinicopathologic factors linked to an increased risk of carrying these mutations.
Clinical activity with MK-6482 was observed in both RCC and non-RCC lesions.
December 04, 2020
The algorithm was applied to 50 patients who underwent radical prostatectomy between 2008 and 2018.
Ten-year data showed high overall survival and recurrence-free survival rates with Mohs surgery in patients with localized penile cancer.
The app also provides patients with a socially distant alternative to in-person visits during the COVID-19 pandemic.
Cancer-specific survival is noninferior for active surveillance compared with primary intervention in select patients with small renal masses suspicious for renal cell carcinoma.
Blue light cystoscopy identified patients with bladder cancer recurrence post-BCG that would have been missed with standard white light cystoscopy alone.
December 03, 2020
A separate analysis presented at SUO assessed the impact of nadofaragene firadenovec on the incidence and time to cystectomy.
Arjun V. Balar, MD, walks through the patient discussion when weighing the use of pembrolizumab (Keytruda).
Of 13 studies evaluated by investigators for the meta-analysis, only 1 was a randomized controlled trial.
Physicians involved in clinical trials should have the patient in mind “from the very conception of the design to the conduct of the study to dissemination of the results,” says Angela B. Smith, MD, MS.
The researchers also determined that healthcare disparities were associated with cystectomy delay.
The vast majority of patients reported being "pleased" with their medical encounter.
The majority of patients surveyed reported having at least some interest in sexual activity following surgery.